Loading clinical trials...
Loading clinical trials...
A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness
Conditions
Interventions
ARGX-113
Locations
52
United States
Investigator Site 42
Carlsbad, California, United States
Investigator Site 8
Los Angeles, California, United States
Investigator Site 33
Orange, California, United States
Investigator Site 21
Palo Alto, California, United States
Investigator Site 41
Jacksonville, Florida, United States
Investigator Site 4
Tampa, Florida, United States
Start Date
March 1, 2019
Primary Completion Date
June 23, 2022
Completion Date
June 30, 2022
Last Updated
July 14, 2023
NCT06312644
NCT07247279
NCT06055959
NCT06149559
NCT04833894
NCT06704269
Lead Sponsor
argenx
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions